5/13/2022 7:17:21 AM
IMV Q1 Loss Per Share $0.13 Vs Loss $0.10 Last Year
4/22/2022 7:08:04 AM
IMV Inc. Names Michael Bailey Chairman Of Board
1/12/2022 7:09:39 AM
IMV Doses First Patient In VITALIZE Phase 2B Clinical Study Evaluating MVP-S With KEYTRUDA In Patients With R/r DLBCL
12/22/2021 7:07:06 AM
IMV Appoints Andrew Hall As CEO, Effective Jan 1
11/30/2021 7:12:31 AM
IMV Says First Patient Dosed In Phase 1b Clinical Study Evaluating Its Lead Compound In Patients With Breast Cancer
11/22/2021 8:07:41 AM
IMV CFO Pierre Labb To Retire On March 31, 2022
8/10/2021 7:59:07 AM
IMV Announces Final Topline Results Of DeCidE1 Clinical Trial In Advanced Recurrent Ovarian Cancer
8/4/2021 8:33:42 AM
IMV: Frederic Ors Steps Down As CEO
7/15/2021 7:07:40 AM
IMV Prices Public Offering Of 14.3 Mln Units At $1.75/unit
5/12/2021 7:09:27 AM
IMV Inc. Q1 Net Loss $7.0 Mln Vs. Net Loss $7.2 Mln Last Year